Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 177
- Registration Number
- NCT06585488
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Peking University
- Target Recruit Count
- 78
- Registration Number
- NCT06541639
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 75
- Registration Number
- NCT06540066
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Second Hospital of Shanxi Medical University
- Target Recruit Count
- 40
- Registration Number
- NCT06536868
- Locations
- 🇨🇳
Jinzhong third people's hospital, Jinzhong, Shanxi, China
🇨🇳Jincheng General Hospital, Jincheng, Shanxi, China
🇨🇳Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
Tislelizumab in People With Colorectal Cancer
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06529523
- Locations
- 🇳🇬
Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇳🇬Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 180
- Registration Number
- NCT06520683
- Locations
- 🇨🇳
Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651, Guangzhou, Guangdong, China
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 30
- Registration Number
- NCT06504901
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 23
- Registration Number
- NCT06504875
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 74
- Registration Number
- NCT06487858
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06456138
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.